NRx Pharmaceuticals Receives FDA Approval for NRX-101 Use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: NASDAQ.COM
- FDA Approval for Expanded Use: NRx Pharmaceuticals announced that the FDA has approved an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine and lurasidone aimed at augmenting accelerated Transcranial Magnetic Stimulation for depression treatment, marking a significant advancement in mental health care.
- Increased Patient Accessibility: While pivotal clinical trials continue, the company has decided to provide NRX-101 to doctors and eligible patients, ensuring that this potentially life-saving treatment is available as quickly as possible to meet the urgent needs of depression sufferers.
- New Study Initiation: NRx Pharmaceuticals has also launched the SPARC-TMS study, which aims to evaluate the efficacy of the NRX-101-TMS combination in treating patients with Treatment-Resistant Depression, further driving innovation in depression treatment.
- Transparent Cost Structure: Initially, patients will only need to cover shipping expenses and costs associated with FDA-required data collection, as the company will not charge for the investigational drug itself, thereby reducing the financial burden on patients and promoting broader access to the medication.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRXP
Wall Street analysts forecast NRXP stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.160
Low
25.00
Averages
37.67
High
48.00
Current: 4.160
Low
25.00
Averages
37.67
High
48.00
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA to Announce Multiple Therapy Decisions in July
- New Ingredient Approval: On June 9, 2026, the FDA approved Bemotrizinol as a new active ingredient for OTC sunscreens for the first time in over two decades, marking a significant milestone that is expected to drive demand for innovative sunscreen products in the market.
- Children's Monitoring System: The FDA cleared Dexcom's Stelo Glucose Biosensor System on June 12, 2026, making it the first OTC continuous glucose monitor for children, which is anticipated to improve accessibility and effectiveness in managing diabetes among pediatric patients.
- Influenza Treatment Innovation: The FDA approved the first generic version of Xofluza on June 17, 2026, providing a single-dose treatment option for acute influenza in patients aged five and older, which is expected to lower treatment costs and enhance patient options.
- Immunotherapy Breakthrough: The FDA authorized Orca Biosystem's Tregzi, the first Treg cell-based immunotherapy for reducing chronic graft-versus-host disease, offering new treatment hope for blood cancer patients undergoing stem cell transplants.
See More
NRx Pharmaceuticals' Subsidiary Launches Depression Treatment
- Treatment Launch: NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated treatment for patients with major depressive disorder using the FDA-cleared Zeta TMS Navigation Systems at clinics in West Palm Beach and Sarasota, marking a transition from research deployment to active patient care.
- Technological Advantage: The Zeta TMS Navigation System employs proprietary RealTrack technology to provide real-time, markerless image guidance in under two minutes, continuously tracking the TMS coil's position relative to the targeted brain region with sub-millimetric accuracy, significantly enhancing treatment precision.
- Platform Expansion: This milestone not only expands HOPE's broader interventional psychiatry platform, which includes ketamine and Spravato delivery, TMS, and Hyperbaric Oxygen Therapy, but also aims to provide a more comprehensive treatment approach for patients with major depressive disorder and other neurological conditions.
- Future Plans: NRx plans to utilize this platform in its upcoming SPARC-TMS trial evaluating NRX-101, a combination of oral D-cycloserine and lurasidone, in patients with depression and suicidality across civilian and military treatment facilities, further diversifying its treatment offerings.
See More
HOPE Therapeutics Launches Zeta-Navigated TMS Treatments
- First Patient Treatments: HOPE Therapeutics has successfully initiated its first Zeta-navigated TMS treatments at clinics in West Palm Beach and Sarasota, Florida, marking a significant transition from research deployment to active patient care, which is expected to greatly enhance treatment outcomes for patients.
- AI Technology Implementation: The Zeta TMS Navigation System employs artificial intelligence and computer vision to provide sub-millimetric image guidance, enabling the registration of a patient's MRI or CT imaging to their facial anatomy in under two minutes, thereby improving treatment precision and efficiency.
- Support for Clinical Trials: The implementation of these treatments aligns with NRx's planned trial of NRX-101 in civilian and military treatment facilities, indicating ongoing advancements in HOPE's interventional psychiatry platform and enhancing its competitiveness in treating patients with depression and suicidality.
- Integrated Treatment Model: HOPE's treatment platform not only includes TMS but also incorporates various therapies such as ketamine and Spravato®, aiming to provide a more comprehensive solution for treatment-resistant depression patients, further solidifying its leadership position in the mental health sector.
See More
NRx Pharmaceuticals Faces Breach of Contract and Misrepresentation Lawsuit
- Lawsuit Background: Kadima Neuropsychiatry Institute and founder Dr. David Feifel have filed a lawsuit against NRx Pharmaceuticals and its subsidiaries in San Diego County Superior Court, alleging breach of contract and misrepresentation in connection with an acquisition agreement, seeking a court order to compel the defendants to close the transaction, which represents a significant percentage of NRx's current market capitalization.
- Missing Financing Commitment: NRx Chairman Dr. Jonathan Javitt approached Dr. Feifel in 2024 with a proposal to acquire Kadima, repeatedly assuring that financing was secured, yet failed to provide sufficient funds as stipulated in the Asset Purchase Agreement signed on May 9, 2025, impacting the acquisition plans.
- Stock Price Volatility: NRx's press release on January 2, 2025, did not mention any financing contingencies, causing its stock to surge over 40% in a single day; however, subsequent statements indicated that the transaction was still subject to
See More
ZETA and HOPE Announce First Patient Treatment with Zeta TMS Navigation System
- FDA-Cleared Treatment System: ZETA SURGICAL and HOPE Therapeutics have announced the first patient treatment using the FDA-cleared Zeta TMS Navigation System at their Florida clinics, marking a significant advancement in psychiatric treatment that is expected to improve outcomes and enhance patients' quality of life.
- Precision Navigation Technology: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and repeatability in treatment delivery, thereby enhancing treatment efficacy.
- Multi-Site Implementation: HOPE Therapeutics has installed the Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, with patient treatments commencing this week, which is anticipated to expand access to personalized TMS therapy and address the needs of patients with treatment-resistant depression.
- Commitment from Industry Leaders: Raahil Sha, Co-Founder of ZETA, stated that the introduction of the Zeta TMS Navigation System will bring surgical-grade accuracy to TMS clinics, driving the ongoing evolution of psychiatric care and improving patient treatment experiences and outcomes.
See More
ZETA and HOPE Announce First Patient Treatment with TMS Navigation System
- First Patient Treatment: ZETA SURGICAL and HOPE Therapeutics successfully conducted the first patient treatment with the FDA-cleared Zeta TMS Navigation System at their Sarasota clinic, marking a significant milestone in precision treatment for depression.
- Technological Innovation: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and reliability in treatment delivery.
- Expanded Treatment Access: The system has been implemented at HOPE's clinics in West Palm Beach and Sarasota, expected to offer personalized TMS therapy to more patients with treatment-resistant depression, thereby enhancing patient quality of life.
- Industry Impact: Raahil Sha, Co-Founder of ZETA, stated that the application of this technology will transform psychiatric care by improving treatment accuracy and personalization, further expanding the clinical applications of TMS across the country.
See More
FDA to Announce Multiple Therapy Decisions in July
- New Ingredient Approval: On June 9, 2026, the FDA approved Bemotrizinol as a new active ingredient for OTC sunscreens for the first time in over two decades, marking a significant milestone that is expected to drive demand for innovative sunscreen products in the market.
- Children's Monitoring System: The FDA cleared Dexcom's Stelo Glucose Biosensor System on June 12, 2026, making it the first OTC continuous glucose monitor for children, which is anticipated to improve accessibility and effectiveness in managing diabetes among pediatric patients.
- Influenza Treatment Innovation: The FDA approved the first generic version of Xofluza on June 17, 2026, providing a single-dose treatment option for acute influenza in patients aged five and older, which is expected to lower treatment costs and enhance patient options.
- Immunotherapy Breakthrough: The FDA authorized Orca Biosystem's Tregzi, the first Treg cell-based immunotherapy for reducing chronic graft-versus-host disease, offering new treatment hope for blood cancer patients undergoing stem cell transplants.
See More
NRx Pharmaceuticals' Subsidiary Launches Depression Treatment
- Treatment Launch: NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated treatment for patients with major depressive disorder using the FDA-cleared Zeta TMS Navigation Systems at clinics in West Palm Beach and Sarasota, marking a transition from research deployment to active patient care.
- Technological Advantage: The Zeta TMS Navigation System employs proprietary RealTrack technology to provide real-time, markerless image guidance in under two minutes, continuously tracking the TMS coil's position relative to the targeted brain region with sub-millimetric accuracy, significantly enhancing treatment precision.
- Platform Expansion: This milestone not only expands HOPE's broader interventional psychiatry platform, which includes ketamine and Spravato delivery, TMS, and Hyperbaric Oxygen Therapy, but also aims to provide a more comprehensive treatment approach for patients with major depressive disorder and other neurological conditions.
- Future Plans: NRx plans to utilize this platform in its upcoming SPARC-TMS trial evaluating NRX-101, a combination of oral D-cycloserine and lurasidone, in patients with depression and suicidality across civilian and military treatment facilities, further diversifying its treatment offerings.
See More
HOPE Therapeutics Launches Zeta-Navigated TMS Treatments
- First Patient Treatments: HOPE Therapeutics has successfully initiated its first Zeta-navigated TMS treatments at clinics in West Palm Beach and Sarasota, Florida, marking a significant transition from research deployment to active patient care, which is expected to greatly enhance treatment outcomes for patients.
- AI Technology Implementation: The Zeta TMS Navigation System employs artificial intelligence and computer vision to provide sub-millimetric image guidance, enabling the registration of a patient's MRI or CT imaging to their facial anatomy in under two minutes, thereby improving treatment precision and efficiency.
- Support for Clinical Trials: The implementation of these treatments aligns with NRx's planned trial of NRX-101 in civilian and military treatment facilities, indicating ongoing advancements in HOPE's interventional psychiatry platform and enhancing its competitiveness in treating patients with depression and suicidality.
- Integrated Treatment Model: HOPE's treatment platform not only includes TMS but also incorporates various therapies such as ketamine and Spravato®, aiming to provide a more comprehensive solution for treatment-resistant depression patients, further solidifying its leadership position in the mental health sector.
See More
NRx Pharmaceuticals Faces Breach of Contract and Misrepresentation Lawsuit
- Lawsuit Background: Kadima Neuropsychiatry Institute and founder Dr. David Feifel have filed a lawsuit against NRx Pharmaceuticals and its subsidiaries in San Diego County Superior Court, alleging breach of contract and misrepresentation in connection with an acquisition agreement, seeking a court order to compel the defendants to close the transaction, which represents a significant percentage of NRx's current market capitalization.
- Missing Financing Commitment: NRx Chairman Dr. Jonathan Javitt approached Dr. Feifel in 2024 with a proposal to acquire Kadima, repeatedly assuring that financing was secured, yet failed to provide sufficient funds as stipulated in the Asset Purchase Agreement signed on May 9, 2025, impacting the acquisition plans.
- Stock Price Volatility: NRx's press release on January 2, 2025, did not mention any financing contingencies, causing its stock to surge over 40% in a single day; however, subsequent statements indicated that the transaction was still subject to
See More
ZETA and HOPE Announce First Patient Treatment with Zeta TMS Navigation System
- FDA-Cleared Treatment System: ZETA SURGICAL and HOPE Therapeutics have announced the first patient treatment using the FDA-cleared Zeta TMS Navigation System at their Florida clinics, marking a significant advancement in psychiatric treatment that is expected to improve outcomes and enhance patients' quality of life.
- Precision Navigation Technology: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and repeatability in treatment delivery, thereby enhancing treatment efficacy.
- Multi-Site Implementation: HOPE Therapeutics has installed the Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, with patient treatments commencing this week, which is anticipated to expand access to personalized TMS therapy and address the needs of patients with treatment-resistant depression.
- Commitment from Industry Leaders: Raahil Sha, Co-Founder of ZETA, stated that the introduction of the Zeta TMS Navigation System will bring surgical-grade accuracy to TMS clinics, driving the ongoing evolution of psychiatric care and improving patient treatment experiences and outcomes.
See More
ZETA and HOPE Announce First Patient Treatment with TMS Navigation System
- First Patient Treatment: ZETA SURGICAL and HOPE Therapeutics successfully conducted the first patient treatment with the FDA-cleared Zeta TMS Navigation System at their Sarasota clinic, marking a significant milestone in precision treatment for depression.
- Technological Innovation: The Zeta TMS Navigation System utilizes RealTrack™ technology to provide real-time, markerless image guidance by registering a patient's MRI or CT imaging to their facial anatomy in under two minutes, ensuring high accuracy and reliability in treatment delivery.
- Expanded Treatment Access: The system has been implemented at HOPE's clinics in West Palm Beach and Sarasota, expected to offer personalized TMS therapy to more patients with treatment-resistant depression, thereby enhancing patient quality of life.
- Industry Impact: Raahil Sha, Co-Founder of ZETA, stated that the application of this technology will transform psychiatric care by improving treatment accuracy and personalization, further expanding the clinical applications of TMS across the country.
See More
